Study Evaluating PAZ-417 in Cerebrospinal Fluid in Subjects With Alzheimer's Disease

Summary

The primary purpose of this study is to assess biomarker known as amyloid beta peptide 40 (Ab40) in Cerebrospinal Fluid (CSF), following a single oral dose of PAZ-417 in subjects with Alzheimer Disease (AD). This study will also consider another biomarker amyloid beta peptide 42 (Ab42) in Cerebrospinal Fluid in subjects with Alzheimer Disease and assess the safety, tolerability and pharmacokinetic profile of PAZ-417 in both plasma and Cerebrospinal Fluid in these subjects.

Timeline

Start

2008-08

Primary completion

2008-12

Completion

2008-12

Drugs

Indications